Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization

Hepatology Research

Volumn 23, Issue 3, 2002, Pages 202-210

  Maeda, Seishi ^a   Fujiyama, Shigetoshi ^a   Tanaka, Motohiko ^a   Ashihara, Hiroshi ^a   Hirata, Rika ^a   Tomita, Kimio ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Local recurrence; Survival; Transcatheter arterial chemoembolization; Transcatheter arterial chemolipiodolization

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; CISPLATIN; DECARBOXYPROTHROMBIN; EPIRUBICIN; IODINATED POPPYSEED OIL; PROTHROMBIN; TUMOR MARKER; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENDER; HUMAN; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; REVIEW; RISK FACTOR; TUMOR VOLUME; ULTRASOUND;

EID: 0037411177     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(01)00174-7     Document Type: Article

References (15)

1. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer 1987;60:1400-11.
2. Nakakuma K, Tashiro S, Hiraoka T, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983;52:2193-200.
3. Kobayashi H, Hidaka H, Kajiya Y, et al. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol 1986;27:139-47.
4. Fujiyama S, Morishita. T, Hashiguchi O, Sato T. Plasma abnormal prothrombin(des-γ-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988;61:1621-8.
5. Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983;19:1053-65.
6. Fukushima S, Kawaguchi T, Nishida M, et al. Selective Anticancer effects of 3′, 5′-dioctanoyl-5-fluoro-2′- deoxyuridine, a lipophilic prodrug of 5-fluoro-2′-deoxyuridine, dissolved in an oily lymphographic agent on hepatic cancer of rabbits bearing VX-2 tumor. Cancer Res 1987;47:1930-4.
7. Shibata J, Fujiyama S, Sato T, et al. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989;64:1586-94.
8. Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemo-embolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semi Oncol 1997;24(Suppl 6):38-45.
9. Bruix J, Llovet JM, Casrells A, Montana X, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-83.
10. Pelletier G, Roche A, Ink O, Anciaux ML, et al. A randomized trial of hepatic arterial chemo-embolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.
11. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan - Report 14. Acta Hepatol Jpn 2000;41:799-811 in Japanese.
12. Tanaka K, Nakamura S, Numata K, et al. Hepatocellular carcinoma: Treatment with percutaneous ethanol injection and trans-catheter arterial embolization. Radiology 1994;185:457-60.
13. Inoue S, Nakao A, Harada A, et al. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol 1994;89:2222-6.
14. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers toward early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2001 (in press).
15. Okusaka T, Okada S, Ishii H, Ikeda H, et al. Phase II study of trans-catheter embolization using zinostatinstimalamer (SMANCS) and gelatin sponge for hepatocellular carcinoma. Proc Am Soc Clin Oncol 1998;17:266a.